Replies to post #21103 on US Stem Cell Inc (USRM)

[StaleyCornell]

Revenues have increased over the past few years. This is ground floor IMO. Awaiting trial results which will bring on the big money...even possible buyout offers.

[Dragon Lady]

Quote LOL, "Why doesn't it matter how much cash they have? Don't trials cost money?
"

BINGO !! LOL, amazing right? They sure as H cost money. $10's and $10's of MILLIONS for large, FDA quality, phase II/III trials. MONEY THIS LITTLE CASH BROKE COMPANY DOES NOT HAVE, and HAS NOT HAD SINCE AT LEAST 2010, PER THEIR OWN DAMN SEC FILINGS !

HOW does $600 to $1K a month in R&D spending per their latest SEC 10-Q, how the H does that fund some fantasy "FDA quality phase II/III trial about to be completed"??? TOTAL NONSENSE is what it is. NOT HAPPENING per the company's own SEC filed commentaries.

THAT is why per their own DAMN SEC FILED 10-K, dated March 2016, they HAVE NO MAJOR PHASE II/III trials presently being conducted or advancing. ALL STOPPED for......LACK OF FUNDING. The company is near cash broke at any given time, a GOING CONCERN, nearly INSOLVENT per the Northstar Biotech LLC lawsuit, which is their largest shareholder, has BOD members on it including the Chairman, and former insiders.

SEC 10-K, March of 2016, NEVER ANY FURTHER SEC FILINGS in 2016, no PR or anything else to change or update what they stated in this 10-K:

https://www.sec.gov/Archives/edgar/data/1388319/000118518516003859/usstemcell10k123115.htm

PAGE 24:

"Risks Related to Product Development

All of our product candidates are in an early stage of development and we may never succeed in developing and/or commercializing them. We depend heavily on the success of our MyoCell product candidate. If we are unable to commercialize MyoCell or any of our other product candidates or experience significant delays in doing so, our business may fail.


·
We have invested a significant portion of our efforts and financial resources in our MyoCell product candidate and depend heavily on its success. MyoCell is currently in the clinical testing stage of development, although we have suspended work under our clinical trials as we seek to raise sufficient funds to complete the trials."

PAGE 38:

"We received approval from the FDA in July of 2009 to conduct a Phase I safety study on 15 patients of a combined therapy (Myocell with SDF-1), which we believe was the first approval of a study combining gene and cell therapies. We initially commenced work on this study, called the REGEN Trial, during the first quarter of 2010. We suspended activity on the trial in 2010 while seeking additional funding necessary to conduct the trial. We are seeking to secure sufficient funds to reinitiate enrollment in the MARVEL and REGEN trials. If we successfully secure such funds, we intend to re-engage a contract research organization, or CRO, investigators and certain suppliers to advance such trials. We have initiated and enrolled our first patient in the MIRROR trial in 2013. The trial is very similar to the MARVEL trial but focuses on sites outside the US. We will continue enrollment in the MIRROR trial once we have secured sufficient funds."

LACK OF FUNDING = NO current phase II/III MARVEL trial advancing. DEAD IN THE WATER, per their own SEC filings. Yepper. Plain English. BLACK n WHITE, never a SEC filing or PR or anything else to contradict those statements above, the LEGALLY BINDING STATEMENT !